Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
暂无分享,去创建一个
[1] Ting-zhuang Yi,et al. Identification of potential biomarkers in Barrett’s esophagus derived esophageal adenocarcinoma , 2021, Scientific Reports.
[2] Ming-Chin Lin,et al. Deep Learning for the Diagnosis of Esophageal Cancer in Endoscopic Images: A Systematic Review and Meta-Analysis , 2022, Cancers.
[3] D. Agrawal,et al. Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis , 2022, International journal of molecular sciences.
[4] Sen Li,et al. Machine Learning and Novel Biomarkers Associated with Immune Infiltration for the Diagnosis of Esophageal Squamous Cell Carcinoma , 2022, Journal of oncology.
[5] J. Qin,et al. Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors , 2022, Esophagus.
[6] G. Kim,et al. MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients , 2022, Journal of Korean medical science.
[7] F. He,et al. Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected , 2022, Biomarker Research.
[8] P. Cravedi,et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis , 2022, Hepatology.
[9] N. Bhattarai,et al. Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma , 2022, Clinical proteomics.
[10] Tian Yang,et al. Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma , 2022, Bioscience reports.
[11] S. Murthy,et al. Esophageal adenocarcinoma: A dire need for early detection and treatment , 2022, Cleveland Clinic Journal of Medicine.
[12] C. Gheorghe,et al. Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck , 2022, Frontiers in Medicine.
[13] F. Dumoulin,et al. Artificial Intelligence in the Management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma , 2022, Cancers.
[14] H. Yip,et al. Performance of screening tests for Oesophageal Squamous Cell Carcinoma: a systematic review and meta-analysis. , 2022, Gastrointestinal endoscopy.
[15] A. Teschendorff,et al. Novel epigenetic network biomarkers for early detection of esophageal cancer , 2022, Clinical epigenetics.
[16] B. Helmink,et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2022, Cell.
[17] A. Bansal,et al. Quantitative proteomic profiling of esophageal adenocarcinoma tumors to assess prevalence of approved targets and elucidate novel biomarkers. , 2022, Journal of Clinical Oncology.
[18] S.-C. Jim Yeung,et al. A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study , 2022, Molecular Cancer.
[19] N. Waddell,et al. ctDNA as a biomarker of progression in oesophageal adenocarcinoma , 2021, ESMO open.
[20] F. Meng,et al. Salivary microbiota may predict the presence of esophageal squamous cell carcinoma , 2021, Genes & diseases.
[21] Gitanjali Goyal,et al. Potential role of noninvasive biomarkers during liver fibrosis , 2021, World journal of hepatology.
[22] D. Agrawal,et al. S431 Proteomic Assay for Barrett’s Esophagus Progression: A Multi-Institutional Retrospective Study , 2021, American Journal of Gastroenterology.
[23] Jun Liu,et al. Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: a systemic review. , 2021, Critical reviews in oncology/hematology.
[24] S. Billan,et al. Pembrolizumab–chemotherapy for advanced oesophageal cancer , 2021, The Lancet.
[25] Sung-Bae Kim,et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.
[26] D. Agrawal,et al. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. , 2021, Journal of gastrointestinal oncology.
[27] Vikrant Rai,et al. The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma , 2021, Biology.
[28] S. Markar,et al. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis , 2021, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[29] S. Hong,et al. Current Status of Image-Enhanced Endoscopy for Early Identification of Esophageal Neoplasms , 2021, Clinical endoscopy.
[30] A. Madabhushi,et al. Artificial Intelligence in Surveillance of Barrett's Esophagus , 2021, Cancer Research.
[31] M. Fassan,et al. Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence , 2021, Cancers.
[32] H. Matsubara,et al. Development of imaging biomarker for esophageal cancer using intravoxel incoherent motion MRI , 2021, Esophagus.
[33] F. Barba,et al. Biomonitoring of Multiple Mycotoxins in Urine by GC–MS/MS: A Pilot Study on Patients with Esophageal Cancer in Golestan Province, Northeastern Iran , 2021, Toxins.
[34] Xiaoshan Feng,et al. Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma , 2021, BMC Cancer.
[35] H. Nagase,et al. Cell-free microRNA-1246 in different body fluids as a diagnostic biomarker for esophageal squamous cell carcinoma , 2021, PloS one.
[36] A. Cervantes,et al. Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Chun Chen,et al. Application of machine learning approaches to predict the 5-year survival status of patients with esophageal cancer , 2021 .
[38] D. Katzka,et al. Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges. , 2021, Gastrointestinal endoscopy clinics of North America.
[39] Tamaki Yamada,et al. Urinary microRNA biomarkers for detecting the presence of esophageal cancer , 2020, Scientific Reports.
[40] T. Zhai,et al. Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy , 2020, Radiation oncology.
[41] Tao Yu,et al. Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Oncology.
[42] C. S. Bang,et al. Computer-aided diagnosis of esophageal cancer and neoplasms in endoscopic images: a systematic review and meta-analysis of diagnostic test accuracy. , 2020, Gastrointestinal endoscopy.
[43] Jian Zhu,et al. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC , 2020, OncoTargets and therapy.
[44] Luis A. de Souza,et al. Endoscopic prediction of submucosal invasion in Barrett’s cancer with the use of artificial intelligence: a pilot study , 2020, Endoscopy.
[45] C. Palm,et al. Standalone performance of artificial intelligence for upper GI neoplasia: a meta-analysis , 2020, Gut.
[46] Luming Huang,et al. Artificial intelligence technique in detection of early esophageal cancer , 2020, World journal of gastroenterology.
[47] Vanessa L. Horner,et al. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. , 2020, Translational gastroenterology and hepatology.
[48] P. Bhosale,et al. Role of precision imaging in esophageal cancer , 2020, Journal of thoracic disease.
[49] Dongsheng Xu,et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors , 2020, Biomarker Research.
[50] C. Richards,et al. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma , 2020, British Journal of Cancer.
[51] Hong Zhao,et al. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials , 2020, Therapeutic advances in medical oncology.
[52] W. Leung,et al. Accuracy of artificial intelligence-assisted detection of upper GI lesions: a systematic review and meta-analysis. , 2020, Gastrointestinal endoscopy.
[53] K. Chiam,et al. Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus , 2020, World journal of gastroenterology.
[54] K. Lam,et al. Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma , 2020, Cancers.
[55] Yiwei Xu,et al. Blood-based biomarkers for early detection of esophageal squamous cell carcinoma , 2020, World journal of gastroenterology.
[56] Michell Lopez,et al. Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis , 2020, World journal of oncology.
[57] H. Baba,et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers , 2020, British Journal of Cancer.
[58] M. Rugge,et al. Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. , 2020, Pathology, research and practice.
[59] B. Takkouche,et al. Salivary biomarkers for cancer diagnosis: a meta-analysis , 2020, Annals of medicine.
[60] N. Merrett,et al. Association of Biomarkers for Human Papillomavirus With Survival Among Adults With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma. , 2020, JAMA network open.
[61] Yuyu Qiu,et al. Discovery of Novel Prognostic Biomarkers and Therapeutic Targets for Esophageal Cancer , 2020 .
[62] P. Sharma,et al. Circulating human papillomavirus DNA detection in Barrett's dysplasia and esophageal adenocarcinoma. , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[63] Mingyao Liu,et al. Chemokines and their receptors as biomarkers in esophageal cancer , 2019, Esophagus.
[64] R. Gurski,et al. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett’s Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study , 2019, Journal of Gastrointestinal Surgery.
[65] Jian Zhu,et al. Prognostic Value of Texture Analysis Based on Pretreatment DWI-Weighted MRI for Esophageal Squamous Cell Carcinoma Patients Treated With Concurrent Chemo-Radiotherapy , 2019, Front. Oncol..
[66] B. Berman,et al. Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma , 2019, Gut.
[67] Lincoln D. Stein,et al. Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma. , 2019, The Annals of thoracic surgery.
[68] H. Matsubara,et al. Imaging biomarkers for the treatment of esophageal cancer , 2019, World journal of gastroenterology.
[69] O. Bodger,et al. Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma , 2019, Scientific Reports.
[70] T. Zander,et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma , 2019, BMC Cancer.
[71] Hongwei Zhang,et al. Advances in prognostic biomarkers for esophageal cancer , 2018, Expert review of molecular diagnostics.
[72] L. Fashoyin-Aje,et al. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 , 2018, The oncologist.
[73] Ke Li,et al. Exploring potential biomarkers of early stage esophageal squamous cell carcinoma in pre- and post-operative serum metabolomic fingerprint spectrum using 1H-NMR method. , 2019, American journal of translational research.
[74] T. Zander,et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma , 2019, BMC Cancer.
[75] Na-Lin Lai,et al. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials , 2018, BMC Cancer.
[76] K. Chiam,et al. ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses , 2018, Annals of Surgical Oncology.
[77] J. Sicklick,et al. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma , 2018, Clinical Cancer Research.
[78] D. Agrawal,et al. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma , 2018, Journal of Gastrointestinal Cancer.
[79] N. Merrett,et al. Survival Rates for Patients With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma With or Without Human Papillomavirus Infection , 2018, JAMA network open.
[80] Tao-Tao Liu,et al. Diagnostic and Prognostic Value of Circulating MicroRNAs for Esophageal Squamous Cell Carcinoma: a Systematic Review and Meta-analysis , 2018, Journal of Cancer.
[81] P. Philip,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.
[82] D. Agrawal,et al. Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen , 2018, Front. Oncol..
[83] A. Barbour,et al. Serum glycoprotein biomarker validation for esophageal adenocarcinoma and application to Barrett’s surveillance , 2018, bioRxiv.
[84] Z. Tian,et al. Identification of the key transcription factors in esophageal squamous cell carcinoma. , 2018, Journal of thoracic disease.
[85] Xu Zhang,et al. Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. , 2017, Molecular and clinical oncology.
[86] Robert A. Smith,et al. Liquid Biopsy for Investigation of Cancer DNA in Esophageal Adenocarcinoma: Cell-Free Plasma DNA and Exosome-Associated DNA. , 2018, Methods in molecular biology.
[87] M. Guan,et al. Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression , 2017, Cell Death & Disease.
[88] D. Agrawal,et al. Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes , 2017, Front. Oncol..
[89] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[90] Jiang Du,et al. Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer , 2017, Oncology letters.
[91] Guoliang Zhang,et al. Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer , 2017, Oncotarget.
[92] D. Donoghue,et al. The importance of regulatory ubiquitination in cancer and metastasis , 2017, Cell cycle.
[93] J. Ajani,et al. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma , 2017, Carcinogenesis.
[94] G. Dakubo. Esophageal Cancer Biomarkers in Circulation , 2017 .
[95] K. Takasaki,et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[96] Thomas D. Wang,et al. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas , 2016, Oncotarget.
[97] G. Dakubo. Cancer Biomarkers in Body Fluids , 2023, Cambridge International Law Journal.
[98] A. Behrens,et al. Diagnostics and Early Diagnosis of Esophageal Cancer , 2015, Visceral Medicine.
[99] D. Agrawal,et al. Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma , 2015, Clinical and translational science.
[100] Joel H Rubenstein,et al. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. , 2015, Gastroenterology.
[101] M. Arnal,et al. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015 .
[102] Michael S. Goldberg,et al. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma , 2015, Cancer Immunology Research.
[103] G. Freeman,et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.
[104] George C. Mayne,et al. Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma , 2015, Journal of Gastrointestinal Surgery.
[105] Masayuki Watanabe. Risk factors and molecular mechanisms of esophageal cancer: differences between the histologic subtypes , 2015 .
[106] A. Ribas,et al. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers , 2015, British Journal of Cancer.
[107] María José Domper Arnal,et al. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.
[108] Wan-Li Liu,et al. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma , 2014, BMC Cancer.
[109] S. Misra,et al. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. , 2014, World journal of gastrointestinal oncology.
[110] J. Dou,et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways , 2014, Cell Death and Disease.
[111] D. Lenschow,et al. The Antiviral Activities of ISG15 , 2013, Journal of Molecular Biology.
[112] A. Sharma,et al. Receptor for Advanced Glycation End Products (RAGE) on iNKT Cells Mediates Lung Ischemia–Reperfusion Injury , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[113] Dongfeng Li,et al. Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal Cancer , 2013, PloS one.
[114] Jun Yang,et al. A Dual Role of Strigolactones in Phosphate Acquisition and Utilization in Plants , 2013, International journal of molecular sciences.
[115] Feiyan Lin,et al. Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro , 2013, Molecular and Cellular Biochemistry.
[116] Zijun Xie,et al. Saliva supernatant miR-21: a novel potential biomarker for esophageal cancer detection. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[117] H. J. Cha,et al. Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. , 2010, Journal of gynecologic oncology.
[118] D. Haines,et al. Ubiquitin and cancer: new discussions for a new journal. , 2010, Genes & cancer.
[119] Robert E. Brown,et al. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. , 2008, Annals of clinical and laboratory science.
[120] J. Isola,et al. The calcium-binding protein S100P in normal and malignant human tissues , 2008, BMC clinical pathology.
[121] Peter D Siersema,et al. Esophageal cancer. , 2008, Gastroenterology clinics of North America.
[122] E. Wolf,et al. Monozygotic Twin Model Reveals Novel Embryo-Induced Transcriptome Changes of Bovine Endometrium in the Preattachment Period1 , 2006, Biology of reproduction.
[123] M. Azuma,et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.
[124] C. Pickart,et al. Ubiquitin: structures, functions, mechanisms. , 2004, Biochimica et biophysica acta.
[125] T. Suter,et al. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. , 2004, Breast.
[126] J. Baraban,et al. ERK and p38 Inhibit the Expression of 4E-BP1 Repressor of Translation through Induction of Egr-1* , 2003, Journal of Biological Chemistry.
[127] J C Reed,et al. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. , 2001, Molecular cell.
[128] Zhijian J. Chen,et al. Activation of the IκB Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin Chain , 2000, Cell.
[129] D. Kelleher,et al. DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[130] B. Korant,et al. Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. , 1986, The Journal of biological chemistry.
[131] M. Pestel. [Chemotherapy of advanced cancers]. , 1960, Concours medical.